Evidence map›Paper›PMID 39606390›Full record

ArticlemedRxiv : the preprint server for health sciences2024

DNA-guided CRISPR/Cas12 for RNA targeting.

Carlos Orosco, Santosh R Rananaware, Boyu Huang, Michael P Hanna, M Reza Ahmadimashhadi, Jordan G Lewis, Michael P Baugh, August P Bodin, Sarah J Flannery, Ian H Lange and 4 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Carlos OroscoDepartment of Chemical Engineering, University of Florida, Gainesville, FL, USA.ORCID 0009-0009-4865-2300
Santosh R RananawareDepartment of Chemical Engineering, University of Florida, Gainesville, FL, USA.ORCID 0000-0001-8789-5799
Boyu HuangDepartment of Chemical Engineering, University of Florida, Gainesville, FL, USA.ORCID 0000-0003-2646-7656
Michael P HannaDepartment of Chemical Engineering, University of Florida, Gainesville, FL, USA.
M Reza AhmadimashhadiDepartment of Chemical Engineering, University of Florida, Gainesville, FL, USA.ORCID 0009-0008-1077-2385
Jordan G LewisDepartment of Chemical Engineering, University of Florida, Gainesville, FL, USA.ORCID 0009-0006-7339-0056
Michael P BaughDepartment of Chemical Engineering, University of Florida, Gainesville, FL, USA.ORCID 0009-0008-8784-5749
August P BodinDepartment of Chemical Engineering, University of Florida, Gainesville, FL, USA.ORCID 0009-0006-8132-8818
Sarah J FlanneryDepartment of Chemical Engineering, University of Florida, Gainesville, FL, USA.ORCID 0009-0008-0436-4975
Ian H LangeDepartment of Chemical Engineering, University of Florida, Gainesville, FL, USA.ORCID 0009-0009-8345-8220
Zoe R FangDepartment of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL, USA.ORCID 0000-0003-0986-1993
Vedant N KaralkarDepartment of Computer Science, University of Florida, Gainesville, FL, USA.ORCID 0000-0002-0623-0582
Katelyn S MeisterDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0002-4642-1949
Piyush K JainDepartment of Chemical Engineering, University of Florida, Gainesville, FL, USA.ORCID 0000-0001-7153-442X

Funding

Discovery and engineering of CRISPR/Cas systemsR35GM147788 · NIGMS · UNIVERSITY OF FLORIDA · PI Piyush K Jain · 2022 to 2026
$1.8M
A rapid CRISPR-based self-testing platform for early detection of HIVR61AI181016 · NIAID · UNIVERSITY OF FLORIDA · PI Piyush K Jain · 2024 to 2026
$1.3M
Rapid detection of Hepatitis C virus using CRISPR/CasR21AI156321 · NIAID · UNIVERSITY OF FLORIDA · PI JAIN, PIYUSH K · 2021 to 2022
$419k
Rapid point-of-care detection of Hepatitis C viral RNA using multiplexed CRISPR/Cas platformsR21AI168795 · NIAID · UNIVERSITY OF FLORIDA · PI JAIN, PIYUSH K · 2022 to 2023
$419k
NIAID NIH HHS R21 AI156321NIAID NIH HHS R21 AI168795NIAID NIH HHS R61 AI181016NIGMS NIH HHS R35 GM147788
6 · The paper itself

Abstract

CRISPR-Cas nucleases are transforming genome editing, RNA editing, and diagnostics but have been limited to RNA-guided systems. We present ΨDNA, a DNA-based guide for Cas12 enzymes, engineered for specific and efficient RNA targeting. ΨDNA mimics a crRNA but with a reverse orientation, enabling stable Cas12-RNA assembly and activating trans-cleavage without RNA components. ΨDNAs are effective in sensing short and long RNAs and demonstrated 100% accuracy for detecting HCV RNA in clinical samples. We discovered that ΨDNAs can guide certain Cas12 enzymes for RNA targeting in cells, enhancing mRNA degradation via ribosome stalling and enabling multiplex knockdown of multiple RNA transcripts. This study establishes ΨDNA as a robust alternative to RNA guides, augmenting the potential of CRISPR-Cas12 for diagnostic applications and targeted RNA modulation in cellular environments.

Identifiers

PMID39606390
PMCPMC11601776

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.